To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Update on biomarkers for … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Contact form


Note! If you want an answer on a question you must specify your email address

Update on biomarkers for amyloid pathology in Alzheimer's disease

Review article
Authors Nicholas Ashton
Michael Schöll
Kerstin Heurling
Eleni Gkanatsiou
Erik Portelius
Kina Höglund
Gunnar Brinkmalm
A Hye
Kaj Blennow
Henrik Zetterberg
Published in Biomarkers in medicine
Volume 12
Issue 7
Pages 799-812
ISSN 1752-0371
Publication year 2018
Published at Institute of Neuroscience and Physiology
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 799-812
Language en
Keywords Alzheimer's diseaseamyloid-βAβbiomarkersblood-based biomarkerscerebrospinal fluiddementiapositron emission tomography
Subject categories Geriatrics, Neurology, Neuroscience, Neurosciences, Biomedical Laboratory Science/Technology


At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology. Furthermore, we will explore the current application of blood-based markers to assess Aβ pathology.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?